Merrimack Pharmaceuticals Dirección
Dirección controles de criterios 2/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Gary Crocker
Chief Executive Officer (CEO)
US$134.2k
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | 7.6yrs |
| Participación del CEO | 0.9% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 6.3yrs |
Actualizaciones recientes de la dirección
Recent updates
We're Not Worried About Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn
Feb 14
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Are In A Position To Invest In Growth
Sep 23Merrimack Pharmaceuticals GAAP EPS of -$0.04
Aug 04Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation
Mar 19We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow
May 19Are Insiders Selling Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock?
Feb 22Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its Business
Jan 01Merrimack Pharma jumps 42% on bullish timeline for potential Onivyde milestone payment
Dec 02Merrimack Pharmaceuticals reports Q3 results
Nov 05Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$1m |
| Dec 31 2023 | US$134k | n/a | -US$1m |
| Sep 30 2023 | n/a | n/a | -US$1m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | -US$2m |
| Dec 31 2022 | US$105k | n/a | -US$2m |
| Sep 30 2022 | n/a | n/a | -US$2m |
| Jun 30 2022 | n/a | n/a | -US$2m |
| Mar 31 2022 | n/a | n/a | -US$2m |
| Dec 31 2021 | US$105k | n/a | -US$2m |
| Sep 30 2021 | n/a | n/a | -US$3m |
| Jun 30 2021 | n/a | n/a | -US$4m |
| Mar 31 2021 | n/a | n/a | -US$4m |
| Dec 31 2020 | US$90k | n/a | -US$3m |
| Sep 30 2020 | n/a | n/a | -US$3m |
| Jun 30 2020 | n/a | n/a | -US$2m |
| Mar 31 2020 | n/a | n/a | -US$11m |
| Dec 31 2019 | US$95k | n/a | -US$21m |
| Sep 30 2019 | n/a | n/a | -US$33m |
| Jun 30 2019 | n/a | n/a | -US$45m |
| Mar 31 2019 | n/a | n/a | -US$53m |
| Dec 31 2018 | US$123k | n/a | -US$61m |
| Sep 30 2018 | n/a | n/a | -US$60m |
| Jun 30 2018 | n/a | n/a | -US$53m |
| Mar 31 2018 | n/a | n/a | -US$64m |
| Dec 31 2017 | US$175k | US$31k | -US$75m |
Compensación vs. Mercado: La compensación total de Gary($USD134.23K) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD1.60M).
Compensación vs. Ingresos: La compensación de Gary ha aumentado mientras la empresa no es rentable.
CEO
Gary Crocker (71 yo)
7.6yrs
Permanencia
US$134,234
Compensación
Mr. Gary L. Crocker, MBA, has been President (Principal Executive Officer) and Treasurer (Principal Financial and Accounting Officer) of Merrimack Pharmaceuticals, Inc. since June 28, 2019. He is Chief Exe...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 20.3yrs | US$134.23k | 0.93% $ 2.1m | |
| Co-Founder & Independent Director | 9.3yrs | US$123.45k | 0.25% $ 568.1k | |
| Member of Scientific Advisory Board | 6.3yrs | US$39.38k | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 6.3yrs | sin datos | sin datos | |
| Chairman of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.7yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 6.3yrs | sin datos | sin datos | |
| Independent Director | 4.7yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 6.3yrs | sin datos | sin datos | |
| Independent Director | 1.9yrs | US$125.45k | 0.029% $ 64.0k |
6.3yrs
Permanencia media
60yo
Promedio de edad
Junta con experiencia: La junta directiva de MACK se considera experimentada (6.2 años de antigüedad promedio).